Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Market Cap	2.77B -26.0%
Revenue (ttm)	418.18M -29.7%
Net Income	55.16M -61.9%
EPS	0.33 -62.2%
Shares Out	164.51M
PE Ratio	51.03
Forward PE	n/a
Dividend	0.20 (1.25%)
Ex-Dividend Date	Jul 10, 2025

Volume	8,474,884
Average Volume	4,645,884
Open	16.00
Previous Close	16.05
Day's Range	15.96 - 17.33
52-Week Range	14.46 - 31.13
Beta	0.37
RSI	46.35
Earnings Date	Apr 23, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People’s Republic of China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 574
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688089

Financial Performance

In 2025, Cabio Biotech (Wuhan)'s revenue was 563.14 million, an increase of 1.36% compared to the previous year's 555.59 million. Earnings were 143.72 million, an increase of 15.71%.